Tritonix.ai

News / Taiwan / economic_daily

LongLife Biotech Reports 21% Revenue Growth in August, Advances CAR001 Trials

Health Technology · Biotechnology · economic_daily · 2026-09-01

6712

LongLife Biotech announced August revenue of NT$109 million, a 21% year-over-year increase, driven by growth in cell therapy and CDMO services.

What Happened

Steady Revenue Growth: LongLife Biotech reported August revenue of NT$109 million, marking a 21% year-over-year and 11% month-over-month increase. Cumulative revenue for the first eight months reached NT$669 million, up 17% compared to the previous year, supported by steady progress in cell storage, manufacturing services, and CDMO operations.

mRNA Technology Trends: The company highlighted the growing global interest in mRNA-based cancer immunotherapy. Recent clinical successes by Moderna and Merck have validated the clinical and commercial potential of this technology for treating refractory cancers, reinforcing the strategic direction of LongLife’s own research.

Clinical Pipeline Progress: LongLife’s core product, CAR001, utilizes AI-assisted design and mRNA non-viral electroporation technology. The therapy has successfully completed Phase I trials and is currently in the Phase IIa stage, focusing on patients with advanced or recurrent refractory solid tumors.

Competitive Edge: By focusing on innovative cell therapy solutions, LongLife aims to provide patients with alternatives to traditional treatments. As clinical trials progress, the company expects to strengthen its position in the solid tumor treatment market.

Read original

More in Health Technology

Handa Pharma Surges Over 6% After Patent Lawsuit Dismissed in US

Health Technology · cnyes · 2026-09-02

Handa Pharma's stock rallied after the original manufacturer dropped a patent infringement lawsuit against its cancer drug HND-039, with expectations of FDA approval this quarter.

6620

Evercyte August Revenue Hits Yearly High of NT$110 Million

Health Technology · cnyes · 2026-09-01

Taiwan-based cell therapy firm Evercyte reported an August revenue of NT$110 million, marking a year-to-date high driven by robust growth in CDMO and cell services.

6712

Yuhan Corp. Secures 131.1 Billion Won API Supply Deal with Global Pharma

Health Technology · yonhap_finance · 2026-09-01

Yuhan Corp. has signed a 131.1 billion won contract to supply active pharmaceutical ingredients to an undisclosed global pharmaceutical company through 2028.

000100

Latest in Taiwan

Taiwan Stocks Plunge 784 Points as TSMC Leads Market Decline

Electronic Technology · economic_daily · 2026-09-02

Taiwan stocks fell 784 points to close at 46,164.72 on Friday, pressured by geopolitical tensions and weakness in major tech stocks like TSMC.

2301, 2303, 2308, 2317, 2327, 2330, 2344, 2383, 2449, 2455, 3008, 3105, 3189, 3231, 3324, 3711, 4958, 5274, 6442, 6515, 8046

Hiwin Mikrosystem Sees Surge in Silicon Photonics Stage Orders Through Q2 2027

Electronic Technology · cnyes · 2026-09-02

Hiwin Mikrosystem reports a massive spike in demand for its silicon photonics inspection platforms, with order visibility extending into Q2 2027. The company is ramping up production capacity to meet the backlog and has introduced new nano-precision control solutions to capture high-end semiconductor market share.

2049, 4576

Silicon Photonics Stocks Surge: Allion and LuxNet Hit Limit Up Amid AI Demand

Electronic Technology · cnyes · 2026-09-02

Optical communication stocks Allion and LuxNet rallied to limit up as the SEMICON Taiwan exhibition and robust AI data center demand drive investor interest.

2330, 3234, 6442

Compeq's Optical Module Expansion Drives Earnings Upgrade and Price Target Hike

Electronic Technology · economic_daily · 2026-09-02

Analysts have raised Compeq's profit forecasts and price targets, citing strong growth in optical modules and satellite communications as key drivers for the company's non-consumer electronics business.

2313